A new study presented at the 2025 American Society of Hematology (ASH) meeting, by Martin Rivas, Ph.D., a cancer researcher at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, revealed that even subtle disruptions in genome architecture can predispose individuals to lymphoma. This finding offers a new perspective on understanding and eventually treating blood cancers.

The study, titled “SMC3 and CTCF Haploinsufficiency Drive Lymphoid Malignancy via 3D Genome Dysregulation and Disruption of Tumor Suppressor Enhancer-Promoter Loops,” introduced a new idea: architectural tumor suppression.